Table 3.

Comparison of histopathologic and cancer-related outcomes between 35 patients with Helicobacter pylori positive gastric cancer and 56 patients with H. pylori negative gastric cancer. Additional comparison included 26 patients with suspected H. pylori gastric cancer (i.e., atrophic gastritis or gastric intestinal metaplasia on gastric biopsy in the setting of negative H. pylori testing).

	H. pylori Positive Gastric Cancer (n=35)	H. pylori Negative Gastric Cancer (n=56)	p-value	H. pylori Positive Gastric Cancer (including suspected) (n=61)	H. pylori Negative Gastric Cancer (excluding suspected) (n=30)	p-value
Cancer Stage
Early (stage 0–1)	12 (34.3)	16 (28.6)	0.308	23 (37.7)	5 (16.7)	0.037
Late (stage 2–4)	23 (65.7)	36 (64.3)		37 (60.7)	22 (73.3)
Missing	0 (0.0)	4 (7.1)		1 (16)	3 (10.0)
Median survival, months	17.3 (5.9–51.8)	14.9 (5.0–28.0)	0.767	15.1 (7.0–33.6)	12.3 (2.9–26.7)	0.711
Cancer-related Death
Yes	18 (51.4)	31 (55.4))	0.49	29 (47.5)	20 (66.7)	0.166
No	16 (45.7)	25 (44.6)		31 (50.8)	10 (33.3)
Missing	1 (2.9)	0 (0.0)		1 (16)	0 (0.0)
Chemotherapy
Yes	17 (48.6)	26 (46.5)	0.860	27 (44.3)	16 (53.3)	0.441
No	14 (40.0)	25 (44.6)		29 (47.5)	10 (33.3)
Missing	4 (11.4)	5 (8.9)		5 (8.2)	4 (13.4)
Radiation
Yes	2 (5.7)	13 (23.2)	0.086	9 (14.8)	6 (20.0)	0.531
No	29 (82.9)	38 (67.9)		47 (77.0)	20 (67.7)
Missing	4 (11.4)	5 (8.9)		5 (8.2)	4 (13.3)
Surgery
Yes	12 (34.3)	16 (28.6)	0.389	23 (37.7)	5 (16.7)	0.118
No	19 (54.3)	37 (66.1)		34 (55.7)	22 (73.3)
Missing	4 (11.4)	3 (5.4)		4 (6.6)	3 (10.0)
Endoscopic Resection
Yes	6 (17.2)	3 (5.4)	0.095	9 (14.8)	0 (0.0)	0.054
No	25 (71.4)	50 (89.2)		48 (78.7)	27 (90.0)
Missing	4 (11.4)	3 (5.4)		4 (6.5)	3 (10.0)